Deflazacort: Phase III data

A double-blind, international Phase III trial in 196 DMD patients showed that once-daily 0.9 and 1.2 mg/kg deflazacort each

Read the full 199 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE